PI Industries Limited announced the outcome of its Board meeting held on February 12, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Significantly, an interim dividend of ₹5.00 per share (500%) was declared, payable by March 13, 2026. The record date for this dividend has been fixed as Monday, February 23, 2026.
Financial Performance Summary (Q3 FY2025-26)
The Board of Directors of PI Industries Limited convened on February 12, 2026, to review and approve the financial performance for the period ending December 31, 2025. The meeting confirmed the Unaudited Standalone and Consolidated Financial Results, along with the Limited Review Reports from the Statutory Auditors.
Standalone Results Highlights (In ₹ Million)
For the quarter ended December 31, 2025:
- Total Income stood at ₹13,459 Million, compared to ₹18,526 Million in the previous quarter (Sep 30, 2025).
- Profit Before Exceptional Item and Tax (PBEIT) was ₹3,655 Million.
- Profit for the period was ₹2,816 Million.
- Basic Earnings Per Share (EPS) stood at ₹18.56.
For the nine months ended December 31, 2025:
- Total Income was ₹50,279 Million.
- Profit Before Exceptional Item and Tax (PBEIT) was ₹15,616 Million.
- Profit for the period was ₹12,370 Million.
- Basic Earnings Per Share (EPS) stood at ₹81.53.
Consolidated Results Highlights (In ₹ Million)
For the quarter ended December 31, 2025:
- Total Income was ₹14,424 Million.
- Profit Before Exceptional Item and Tax (PBEIT) was ₹2,578 Million.
- Profit for the period was ₹3,113 Million (after recognizing an Exceptional Item gain of ₹1,051 Million).
- Basic Earnings Per Share (EPS) stood at ₹20.52.
For the nine months ended December 31, 2025:
- Total Income was ₹53,836 Million.
- Profit Before Exceptional Item and Tax (PBEIT) was ₹12,905 Million.
- Profit for the period was ₹11,206 Million.
- Basic Earnings Per Share (EPS) stood at ₹73.87.
Interim Dividend Declaration
The Board has approved an interim dividend of ₹5.00 per equity share (face value of ₹1.00 each), representing 500%. This dividend will be paid to eligible members on or before Friday, March 13, 2026. The Company has set Monday, February 23, 2026, as the record date for determining entitlement.
Key Notes on Exceptional Items
The financial results include adjustments related to regulatory changes concerning employee benefits. The notification of the ‘New Labour Codes’ effective from November 21, 2025, necessitated a reassessment of employee obligations. Consequently, an incremental liability of ₹206 Million (Standalone) and ₹209 Million (Consolidated) recognized as an “Exceptional Item” due to this regulatory shift, which is considered non-recurring.
Furthermore, in the Consolidated results, a write-back of contingent consideration amounting to ₹1,260 Million related to the acquisition of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited was recognized as an “Exceptional Item” due to successful in-house business development.
Segment Reporting Overview
Segment analysis confirms that the primary business remains ‘Agro Chemicals’. In the consolidated segment results for the nine months ended December 31, 2025:
- Agro chemicals segment reported a Profit Before Tax of ₹13,956 Million on Revenue of ₹49,556 Million.
- Pharma segment reported a Loss Before Tax of (₹999) Million.
The meeting commenced at 2:00 P.M. (IST) and concluded at 6:30 P.M. (IST).
Source: BSE
